Covid-19 prevention mechanism of the world’s first DNA technology vaccine

Avatar of Nick John By Nick John Dec26,2023 #Covid #prevention
Covid-19 prevention mechanism of the world's first DNA technology vaccine 6
Covid-19 prevention mechanism of the world's first DNA technology vaccine 6

On August 22, ZyCov-D from India-based pharmaceutical company Zydus Cadila became the world’s first DNA vaccine against Covid-19 approved.

Before there were mRNA and DNA technology vaccines, pharmaceutical companies around the world focused on two main goals.

How does ZyCov-D vaccine work?

Pfizer and Moderna vaccines are prepared using mRNA technology, capable of stimulating human cells to produce viral proteins.

Meanwhile, DNA vaccines do not use the entire virus.

ZyCov-D is a `plasmid DNA` vaccine – a recent breakthrough research direction.

Simulate the immune system response when injecting DNA technology vaccines.

Most current Covid-19 vaccines require two doses, except Johnson & Johnson, which injects one dose.

ZyCov-D was developed by the Government’s Department of Biotechnology and the Indian Council of Medical Research (ICMR).

How safe and effective is the vaccine?

ZyCov-D has been in three-phase clinical trials with more than 28,000 participants.

In December 2020, Mr. Pankaj R Patel, president of Zydus Group, reported that the first and second phase trials showed that the vaccine was `safe and immunogenic`.

Covid-19 prevention mechanism of the world's first DNA technology vaccine

A person is vaccinated against Covid-19 at Dr.

A day after Zycov-D was licensed, manufacturer Zydus announced the vaccine was 66% effective against the Delta variant.

`We have not recorded a breakthrough infection by any other variant after vaccination. The trials are not yet completed. We have about 4 to 6 months left to submit all the data of the phase three study.

`Both in adults and children, we have not recorded any serious side effects,` he added.

Advantages and limitations of DNA vaccines

Scientists say DNA vaccines are relatively cheap, safe and stable.

However, in the past, many DNA vaccines failed in testing on human infectious diseases.

According to her, the challenge lies in introducing plasmid DNA into human cells to create a sustainable immune response.

Another limitation of ZyCoV-D is its three-dose mechanism, which can be expensive and put pressure on the health system.

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *